Navigation Links
BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
Date:5/8/2008

- Memorial Sloan-Kettering Cancer Center Investigators to Assess BSI-201

Therapy in BRCA-Negative Ovarian Cancer Patients -

BRISBANE, Calif., May 8 /PRNewswire/ -- BiPar Sciences, Inc. today announced the expansion of Phase 2 clinical trial programs for its lead product, BSI-201, in ovarian cancer. This is the third major clinical trial of BSI-201 that BiPar has launched in the past 6 months, expanding on on-going trials in breast and brain cancer.

The company is evaluating BSI-201, the first poly ADP-ribose polymerase (PARP) inhibitor in its DNA repair portfolio, as a monotherapy for patients whose ovarian cancer is linked to a hereditary genetic defect. Clinicians at Memorial Sloan-Kettering Cancer Center will enroll patients who have a mutation in their BRCA1 or BRCA2 genes.

"We believe BSI-201 holds great promise as a targeted therapy in this difficult-to-treat type of ovarian cancer," said Carol Aghajanian, M.D., co- principal investigator and chief of the gynecologic medical oncology service at Memorial Sloan-Kettering Cancer Center. "BRCA-negative patients are at higher risk of breast and ovarian cancer because BRCA plays a key role in repairing DNA errors that lead to tumor formation."

Ovarian cancer strikes more than 21,000 women a year in the United States and is one of the most common causes of cancer death in women, killing more than 15,000 annually in the United States. Patients with the hereditable BRCA- negative form of the disease account for about 15 percent of the patient population. Women with defective BRCA genes are also at considerably higher risk of breast cancer.

"We have identified a number of important types of cancer where PARP plays a crucial role in tumor growth, and we believe that BRCA-negative ovarian cancer represents another excellent target for BSI-201," said Barry Sherman, M.D., BiPar's Executive Vice President of Development. "We will soon have patients enrolled in four separ
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
2. BiPar Begins Phase 2 Study of Lead PARP Inhibitor in Triple-Negative Breast Cancer Based on Overexpression Biomarker Data
3. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
4. BiPar Announces Preclinical Data Demonstrating Anti-Tumor Activity With BSI-401, Its Second-Generation PARP Inhibitor
5. BiPar Expands Management Team to Advance Lead PARP Inhibitor Product Candidate Into Phase 2 Trials for Cancer
6. Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia
7. Neurocrine Biosciences Reports First Quarter 2008 Results
8. Caliper Life Sciences Optical Imaging Technology Selected to Aid Tuberculosis Research Efforts by the Texas A&M Health Science Center
9. Human Genome Sciences Completes Enrollment in First of Two Phase 3 Lymphostat-B(R) Trials
10. Edwards Lifesciences Announces First Implants in U.S. Study of Minimally-Invasive Pulmonic Valve
11. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 2014  Patients in today,s changing health care landscape ... an outpatient setting versus a hospital. In an effort ... that patients continue to receive high quality medical care; ... new internal medicine residency program. The program,s progressive curriculum ... clinic and even virtual settings. "We ...
(Date:9/15/2014)... 15, 2014 /PRNewswire-iReach/ -- Asthma is a chronic ... ages, but most commonly starts in childhood. It ... of the airways, leading to airflow limitation and ... contact with endogenous and exogenous irritants. Exposure to ... swelling of the airways, tightening of the respiratory ...
(Date:9/15/2014)... 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... owned subsidiary, Valeant Pharmaceuticals International, will redeem all of ... 6.75% Senior Notes due 2017, CUSIP Nos. 91911XAL8, U9098VAD4 ... has mailed an irrevocable notice of redemption for the ... of the irrevocable notice of redemption with respect to ...
Breaking Medicine Technology:Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 2Kaiser Permanente Hawaii Launches New Internal Medicine Residency Program 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 2Asthma Market to Reach 161.02 million Cases in 10MM by 2023 3Asthma Market to Reach 161.02 million Cases in 10MM by 2023 4Asthma Market to Reach 161.02 million Cases in 10MM by 2023 5Valeant Announces Redemption of All of the Outstanding $500.0 Million Aggregate Principal Amount of its 6.75% Senior Notes due 2017 2
... AARP Illinois Disappointed By Senate Vote Against Lower Prescription Drug ... on Tuesday night rejected an amendment to the Patient Protection ... more affordable by allowing for the safe and legal importation ... endorsed by AARP and sponsored by Senators Dorgan, Snowe, McCain, ...
... , SALT LAKE CITY, Dec. 16 ... or the "Company"), a medical device company engaged in the ... announced today that Joe Pepper, PhD, has been appointed to ... Hungerford commented, "Joe has extensive experience running small to large ...
Cached Medicine Technology:AARP Illinois Key Vote News Alert 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 2In Preparation for Commercialization of SVARA(TM), TechniScan Appoints Joe Pepper, PhD to Board of Directors 3
(Date:9/15/2014)... York, New York (PRWEB) September 15, 2014 ... C.R. Bard, Inc. continue to move forward in the ... Southern District of West Virginia, Bernstein Liebhard LLP reports. ... issued a Final Order on September 10th that provides ... The Order notes that none of the affected plaintiffs ...
(Date:9/15/2014)... studies, approximately one out of every 40 individuals in the ... spinal muscular atrophy (SMA), a neurodegenerative disease that causes muscles ... Missouri have made a recent breakthrough with the development of ... models of the disease. In April, a patent was filed ... our lab is using to fight SMA is to ,repress ...
(Date:9/15/2014)... 2014 This year, Avenidas Village ... 2007. To mark the special occasion, Avenidas Village would ... village and helping it to get started seven years ... fun community for seniors. Members of Avenidas Village maintain ... in their own homes. They are able to have ...
(Date:9/15/2014)... Sept. 15, 2014 (HealthDay News) -- Births of multiple ... and death than singleton births, researchers report. The ... in vitro fertilization (IVF) could ease some of that ... have increased in tandem with births to older mothers ... from the University of New South Wales, Australia. ...
(Date:9/15/2014)... 2014 Providing additional expertise to ... LLP (“the Firm”) is proud to welcome ... with the Firm’s Litigation Support Services ... experience, Wolf will assist clients in litigation support, ... advisory matters. He will also provide guidance in ...
Breaking Medicine News(10 mins):Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:C.R. Bard Transvaginal Mesh Lawsuits Move Forward, With Issuance of New Order in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3Health News:Researcher develops and proves effectiveness of new drug for spinal muscular atrophy 2Health News:Avenidas Village Celebrates Anniversary 2Health News:Study Ties Multiple Births to Higher Costs, Complications 2Health News:Study Ties Multiple Births to Higher Costs, Complications 3Health News:Cherry Bekaert Expands its Litigation Support Services Team Capabilities with the Addition of Steven Wolf 2Health News:Cherry Bekaert Expands its Litigation Support Services Team Capabilities with the Addition of Steven Wolf 3
... , NEW YORK, Nov. 18 WAT,s-THE-WORD?! is the first ... products, discoveries on the web and real-life experiences from a ... boys who helped their parents conceive the brand WAT-AAH! ... mom a "cooler" and better name for water, thus WAT-AAH!. ...
... 18 Banfield, The Pet Hospital® today announced ... its medical specialist/nutritionist. With nearly 20 years experience in veterinary ... platform that will position Banfield as a leader in veterinary ... as part of the Medical Quality Advancement team at Banfield,s ...
... , WASHINGTON, Nov. 18 The Union Labor ... subsidiary of ULLICO Inc., a privately held financial and ... provide pharmacy benefit management services to labor group clients. ... union employers and their members with a comprehensive pharmacy ...
... Institutet have discovered that patients with recent-onset schizophrenia have ... findings offer hope of being able to treat schizophrenia ... The causes of schizophrenia are largely unknown, and this ... that infections caught early on in life might increase ...
... have shown that lipid peroxidation stimulates collagen production ... plays an important role in the development of ... carbon tetrachloride, cholestasis and alcohol induced liver fibrosis ... effect of green tea in dimethylnitrosamine (DMN)-induced models ...
... stall carotid artery disease , WEDNESDAY, Nov. 18 (HealthDay ... additional benefit to seniors with coronary artery disease who ... , The 18-month study of 145 Baltimore-area men and ... arterial wall thickness reductions between those who took 1,500 ...
Cached Medicine News:Health News:WAT-AAH!, The First Functional Bottled Water For Kids, Announces The Release of WAT's-THE-WORD?! 2Health News:Banfield, The Pet Hospital(R) Welcomes Board Certified Nutritionist, Medical Specialist to Practice 2Health News:Banfield, The Pet Hospital(R) Welcomes Board Certified Nutritionist, Medical Specialist to Practice 3Health News:Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 2Health News:Union Labor Life Selects Prescription Solutions To Provide Pharmacy Benefit Management Services 3Health News:Immune system activated in schizophrenia 2Health News:Niacin Adds No Benefit for Statin Patients: Study 2
... is a threaded titanium anchor, ... procedures. The anchor features wide ... to optimize bone purchase, as ... to prevent suture binding. Fastin ...
The GII titanium anchor is the "Gold Standard" for soft tissue reattachment to bone. The GII's small size, high pull-out strength and wide range of clinical applications make it the anchor of choice ...
... 'proximal protection' -- providing complete protection from ... vessels with side branches. , ,Proxis ... does not require the attachment or exchange ... debris. ,Proxis is compatible with all ...
... System is the Fischer answer to cost ... specialist. The EP-X system is a highly ... dedicated EP lab system. Ease of access ... Pulsed Progressive Fluoroscopy (PPF) are but a ...
Medicine Products: